middle.news
How Will Prescient’s $7M Raise Accelerate PTX-100’s Fight Against Cancer?
9:18am on Tuesday 1st of July, 2025 AEST
•
Biotechnology
Read Story
How Will Prescient’s $7M Raise Accelerate PTX-100’s Fight Against Cancer?
9:18am on Tuesday 1st of July, 2025 AEST
Key Points
Share Purchase Plan targets $7 million at $0.040 per share
16.7% discount to 15-day volume weighted average price
Funds dedicated to advancing PTX-100 through Phase 2 clinical trials
PTX-100 holds FDA Orphan Drug Designation for Cutaneous T Cell Lymphomas
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Prescient Therapeutics (ASX:PTX)
OPEN ARTICLE